Comparison

AHK-Cu vs
GHK-Cu

Two copper-binding tripeptides, one amino acid apart. One has small human skin studies and a 2018 cosmetic safety review; for the other, we found one laboratory study in PubMed.

Short answerCompound research · 5 min read · Updated 18 Nov 2026

AHK-Cu and GHK-Cu are copper complexes of two tripeptides that differ in one amino acid: alanine in AHK, glycine in GHK. GHK-Cu, listed in cosmetics as copper tripeptide-1, has small human skin studies and a 2018 US cosmetic safety review. For AHK-Cu, PubMed lists one laboratory study, and the one human study on ClinicalTrials.gov mixes it with other peptides.

Key takeaways

  • AHK is Ala-His-Lys and GHK is Gly-His-Lys: one amino acid differs, and the AHK peptide is 14 g/mol heavier.
  • GHK-Cu’s cosmetic ingredient name is copper tripeptide-1; we could not confirm an official cosmetic ingredient name for AHK-Cu.
  • PubMed lists one record naming AHK-Cu, a 2007 laboratory study of human hair follicles; GHK-Cu has small human skin studies, mostly conference reports.
  • A 2026 evidence-map review says AHK-Cu “rests on a thin, poorly characterized evidence base”, and that GHK-Cu’s clinical evidence “remains sparse”.
  • FDA’s compounding page lists injectable GHK-Cu, and Australia’s TGA names GHK-Cu among unapproved peptide products; neither mentions AHK-Cu.

01AHK-Cu vs GHK-Cu in one table

The same questions for both, dated 18 November 2026.

QuestionAHK-CuGHK-Cu
What it isCopper(II) complex of the tripeptide L-alanyl-L-histidyl-L-lysine (Ala-His-Lys)Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys)
The differenceAlanine in first positionGlycine in first position
Peptide mass, without copper354.41 g/mol340.38 g/mol
Cosmetic ingredient (INCI) nameNot confirmed at an official sourceCopper tripeptide-1; also prezatide copper, GHK copper
OriginSyntheticGHK was isolated from human plasma in 1973
PubMed records naming it in the title or abstract (18 Nov 2026)1More than 100, depending on the names searched
Laboratory and animal evidenceOne study (2007): human hair follicles kept alive outside the body, and cultured cells (T4)Many cell and animal studies (T4, T3)
Human studiesNone published that we found. One registered study includes it in a multi-peptide skin serum with GHK-Cu; no resultsSmall, short skin studies, mostly conference reports; one PubMed-indexed randomised trial of a skin-care regimen, with 13 completers, found no objective difference. Four registered skin studies, three with other active ingredients, none with posted results
Independent review (2026)“Shares the motif but rests on a thin, poorly characterized evidence base”Clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”
US cosmetic safety reviewNot named in the 2018 CIR review summaryCIR, an industry-funded panel, 2018: no safety concern at the low concentrations used in cosmetics
FDA compounding pageNot listedListed for injectable routes among withdrawn Category 2 nominations, citing possible immune reactions
Australia (TGA, Apr 2026)Not named in the unapproved-peptides advisoryNamed among examples of unapproved peptide products, “often supplied in injectable form”
WADANot named on the 2026 or 2027 List; check with your anti-doping bodyNot named on the 2026 or 2027 List; check with your anti-doping body

02Are AHK-Cu and GHK-Cu the same molecule?

No. Both are three amino acids bound to copper, and two of the three are the same: histidine and lysine. The first differs: AHK-Cu has alanine where GHK-Cu has glycine. That makes the AHK peptide 354.41 g/mol against 340.38 g/mol for GHK, a gap of 14 g/mol that a mass spectrometry result can show (mass spectrometry explained).

Both hold copper(II) through histidine. A 2026 review describes GHK-Cu as an endogenous tripeptide binding copper one-to-one through histidine, backbone nitrogens and its amino end, and AHK-Cu as a synthetic peptide with “histidine-anchored” copper binding that “shares the motif”. Why the copper makes GHK-Cu blue: why is GHK-Cu blue?

Names. GHK-Cu’s cosmetic ingredient (INCI) name is copper tripeptide-1, and prezatide copper is another name for it. For AHK-Cu we could not confirm an official cosmetic ingredient name: PubChem’s record lists none, and the EU’s CosIng inventory did not load for our tools on 18 November 2026. Research on one is not research on the other, so a label or lab report should name the exact peptide.

03How have AHK-Cu and GHK-Cu been studied?

Very unevenly. Cell and laboratory findings are not evidence of an effect in people.

AHK-Cu. PubMed lists one record that names AHK-Cu in its title or abstract (18 November 2026): a 2007 study at Seoul National University that applied it to human hair follicles kept alive outside the body and to cultured dermal papilla cells, and measured follicle elongation, cell growth and markers of cell death (T4). On ClinicalTrials.gov, one registered study names it: an early phase 1, single-group study planned for 48 adults that tests several agents, including a skin serum containing AHK-Cu, GHK-Cu and three other peptides, with untreated skin sites as controls. It is enrolling by invitation, has no results, and cannot separate either copper peptide’s contribution.

GHK-Cu. More than 100 PubMed records name GHK-Cu in the title or abstract: 105 under GHK-Cu, copper tripeptide-1, prezatide and their spelling variants (18 November 2026). Its research is mostly in cells and animals. The human studies applied it to the skin: small, short cosmetic studies, most reported as conference posters and known through a 2018 review by GHK’s discoverer, and one PubMed-indexed randomised trial of a skin-care regimen after laser resurfacing, in which 13 people completed and objective measures found no difference. A 2026 systematic review describes the human literature as “thin and fragmented”, and found that about 35% of the GHK-Cu primary literature it included lists Loren Pickart or Anna Margolina of Skin Biology Inc. as authors. Detail: topical GHK-Cu and the GHK-Cu research guide.

Independent reviewers. A 2026 evidence-map review in Pharmaceutics, whose authors declare no conflicts of interest, compared GHK-Cu with related copper peptides. It wrote that AHK-Cu “shares the motif but rests on a thin, poorly characterized evidence base”, and that GHK-Cu’s clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”. We found no study that compared them (PubMed and ClinicalTrials.gov, 18 November 2026). Hair-specific research on both: copper peptides and hair.

04How do cosmetic and medicines rules treat AHK-Cu and GHK-Cu?

In a cosmetic, either falls under the same product rules. The differences are in what has been reviewed and what regulators have named.

United States. FDA says “cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market”, and that whether a product is a cosmetic or a drug “is determined by a product’s intended use”. In 2018 the Cosmetic Ingredient Review panel, which the cosmetics industry’s trade association funds and which describes its process as independent, assessed tripeptide-1 (GHK), its metal salts and related ingredients. It noted that copper tripeptide-1 is used in cosmetic products and wrote that “the low use concentrations and negative safety test data reviewed obviate any concerns relating to the safety of these ingredients in cosmetic products”. Its published summary does not name AHK-Cu. Separately, FDA’s compounding page lists GHK-Cu for injectable routes among substances whose Category 2 nominations were withdrawn, citing possible immune reactions; AHK-Cu does not appear on it (page current 22 April 2026).

EU and Great Britain. Each cosmetic product needs a safety assessment before sale, whichever peptide it contains. We could not read the EU’s CosIng ingredient inventory for either name. In the UK, the MHRA decides whether “the claims that are made or the active substance(s) present” make a borderline product a medicine.

Australia. The TGA’s April 2026 safety advisory names GHK-Cu among examples of unapproved peptide products, “often supplied in injectable form”; it does not name AHK-Cu. We read it on the Internet Archive capture of 10 August 2026, because tga.gov.au did not respond. We have not verified how Australian rules treat a cosmetic containing either. More: peptides in skincare.

Sport. Neither is named on WADA’s 2026 Prohibited List or on the 2027 List, in force from 1 January 2027. Class S0 covers any pharmacological substance not addressed elsewhere “and with no current approval by any governmental regulatory health authority for human therapeutic use”; anti-doping organisations decide how it applies. See peptides and anti-doping.

05What we don’t know about AHK-Cu and GHK-Cu

  • Anything about AHK-Cu in people. We found no published human study of it, and the one registered study mixes it with other agents.
  • How the two compare. We found no study that tested them side by side.
  • AHK-Cu’s official cosmetic ingredient name and EU inventory status, which we could not confirm.
  • The long-term safety of either in people, and anything about injected AHK-Cu.
  • Which copper peptide a product holds. Only an identity result on that lot’s lab report can show it: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. PubChem. AHK-Cu, CID 168431292 (monohydrochloride, CAS 682809-81-0); L-alanyl-L-histidyl-L-lysine, CID 7408502 (354.41 g/mol); glycyl-L-histidyl-L-lysine, CID 73587 (340.38 g/mol; synonym tripeptide-1); prezatide copper, CID 71587328 (synonyms copper tripeptide-1 [INCI], GHK copper). Compound records, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/168431292
  2. Pyo HK, Yoo HG, Won CH, et al. [Laboratory study of AHK-Cu on human hair follicles kept alive outside the body and on cultured dermal papilla cells]. Arch Pharm Res, 2007;30(7):834–839. PMID 17703734. pubmed.ncbi.nlm.nih.gov/17703734/
  3. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. [Evidence-map review of GHK-Cu chemistry, formulation and evidence, with a comparison of related copper peptides (Table 4)]. Pharmaceutics, 2026;18(9):1077. PMID 42797253 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC13610439/
  4. Najafi N, Maatouk H, Vardanyan KG, et al. [Systematic review of the GHK-Cu literature, 2005–2026, with a note on concentration of authorship]. Arch Intern Med Res, 2026;9(3):269–293. PMID 42787770. pubmed.ncbi.nlm.nih.gov/42787770/
  5. Pickart L, Margolina A. [Review of GHK-Cu research, including summaries of small skin studies, by GHK’s discoverer]. Int J Mol Sci, 2018;19(7):1987. PMID 29986520. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  6. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171. pubmed.ncbi.nlm.nih.gov/16847171/
  7. ClinicalTrials.gov. NCT07888595 (early phase 1, single group, estimated 48 adults; enrolling by invitation; no results) and searches for “AHK-Cu”, “GHK-Cu” and “copper tripeptide-1”. Registry record and searches, read 18 Nov 2026. clinicaltrials.gov/study/NCT07888595
  8. Johnson W Jr, Bergfeld WF, Belsito DV, et al. Safety assessment of tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 as used in cosmetics. Int J Toxicol, 2018;37(3 suppl):90S–102S (abstract read 18 Nov 2026). Panel funding: cir-safety.org/about, read 18 Nov 2026. doi.org/10.1177/1091581818807863
  9. U.S. Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?) Web page, content current as of 11 Sep 2024; read 18 Nov 2026. And: Certain bulk drug substances for use in compounding that may present significant safety risks, content current as of 22 Apr 2026, read 18 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic…
  10. Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Guidance, last updated 2 Jul 2026; read 18 Nov 2026. Regulation (EC) No 1223/2009, Article 10, and the GB Office for Product Safety and Standards guidance, read 18 Nov 2026. www.gov.uk/guidance/borderline-products-how-to-tell-if-your-…
  11. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026; read on the Internet Archive capture of 10 Aug 2026, the newest capture, because tga.gov.au did not respond on 18 Nov 2026. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  12. World Anti-Doping Agency. Prohibited List 2027 (in force 1 Jan 2027), class S0; Prohibited List 2026. International Standard; 2027 PDF searched 18 Nov 2026; 2026 PDF searched on the Internet Archive capture of 1 Oct 2025, the newest capture holding the file. www.wada-ama.org/en/prohibited-list
  13. PubMed searches run 18 Nov 2026: (“AHK-Cu” OR “AHK Cu”)[tiab] and AHK[tiab] AND copper[tiab], 1 record each (PMID 17703734); “copper tripeptide-3”[tiab], none; (“GHK-Cu” OR “GHK Cu” OR “copper tripeptide-1” OR prezatide OR “Cu-GHK”)[tiab], 99 records; with spelling variants (GHK-copper, copper-GHK, GHK copper, Cu(II)-GHK and others), 105; wider AHK terms (Ala-His-Lys, alanyl-histidyl-lysine, tripeptide-3), 46 records, none other about AHK-Cu. Database searches. pubmed.ncbi.nlm.nih.gov/?term=%22AHK-Cu%22%5Btiab%5D+OR+%22A…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What is the difference between AHK-Cu and GHK-Cu?

One amino acid: AHK-Cu has alanine where GHK-Cu has glycine, and both bind copper through histidine. GHK-Cu has small human skin studies and a 2018 US cosmetic safety review; for AHK-Cu we found one laboratory study.

Is AHK-Cu the same as copper tripeptide-3?

We could not confirm that name at an official source. PubChem’s record for AHK-Cu lists no cosmetic ingredient name, and the EU’s CosIng inventory did not load for our tools. GHK-Cu’s cosmetic name, copper tripeptide-1, is confirmed.

Has AHK-Cu been tested in people?

We found no published human study of AHK-Cu (PubMed, 18 Nov 2026). One study registered on ClinicalTrials.gov applies a serum containing AHK-Cu, GHK-Cu and other peptides to skin; it has no results and cannot separate their contributions.

Is GHK-Cu the same as copper tripeptide-1?

Yes. Copper tripeptide-1 is its cosmetic ingredient name; prezatide copper is another name for the same complex.

Are AHK-Cu and GHK-Cu on the WADA Prohibited List?

Neither is named on the 2026 or 2027 List. Class S0 covers pharmacological substances with no current government approval for human therapeutic use, and anti-doping organisations decide how it applies.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page